Home › Funds › Context Capital Management, LLC › VRDN

Context Capital Management, LLC position in VRDN

VIRIDIAN THERAPEUTICS INC · Health Care

Context Capital Management, LLC reported holding 49,000,000 shares of VRDN (VIRIDIAN THERAPEUTICS INC) in its Q3 2026 13F filing — a position valued at US$56.5M, representing 1.87% of its reported portfolio and ranking #19 among its reported holdings. Context Capital Management, LLC has disclosed VRDN holdings in 2 of the last 2 reported quarters, going back to Q2 2026.

Latest position (Q3 2026)49.00M sh
Reported value held$56.47M
Portfolio Weight1.87%
First reportedQ2 2026
Last changeAdd
Updated2026-11-13

Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR

How Context Capital Management, LLC's VRDN position evolved

Context Capital Management, LLC first disclosed a stake in VRDN in Q2 2026 at 40,750,000 shares (US$43.8M). The position peaked in Q3 2026 at 49,000,000 shares, worth US$56.5M. Across 2 filings, Context Capital Management, LLC increased the stake 1 time(s), trimmed it 0 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 49,000,000 shares valued at US$56.5M — an increase of 8,250,000 shares quarter over quarter..

Quarter by quarter

QuarterSharesValueChange
Q2 2026 40.75M $43.82M New
Q3 2026 49.00M $56.47M Add

Dots on the line are colored by change type; missing quarters mean no position was reported.

About VRDN and 13F data

VRDN (VIRIDIAN THERAPEUTICS INC) is a Health Care company. 35 other funds we track also report a position in VRDN — the largest reported positions include Bellevue Group AG (US$123.7M), Paradigm Biocapital Advisors LP (US$123.5M), Kynam Capital Management, LP (US$118.6M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding VRDN

All VRDN fund holders →

FAQ

How long has Context Capital Management, LLC held VRDN?

Context Capital Management, LLC has disclosed VRDN holdings in 2 of the last 2 reported quarters, going back to Q2 2026.

What is Context Capital Management, LLC's current position in VRDN?

As of Q3 2026, Context Capital Management, LLC holds 49.00M shares of VRDN (VIRIDIAN THERAPEUTICS INC), valued at $56.47M, representing 1.87% of its reported portfolio and ranking #19.

Has Context Capital Management, LLC been buying or selling VRDN?

In the latest 13F filing (Q3 2026), Context Capital Management, LLC increased its position in VRDN. The position peaked in Q3 2026 at 49.00M shares.

Which other funds hold VRDN?

Other major institutional holders of VRDN include Bellevue Group AG, Paradigm Biocapital Advisors LP, Kynam Capital Management, LP, among 35 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.